Core B: Clinical Core

核心 B：临床核心

• 批准号: 10264289
• 负责人: Jesse Benjamin Mez
• 金额: $ 89.21万
• 依托单位: BOSTON UNIVERSITY MEDICAL CAMPUS
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-15 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10264289
• 关键词: 3-Dimensional; Address; Administrative Supplement; Age; Aging; Alzheimer' s Disease; Alzheimer' s disease related dementia; American; Amyloid; Automobile Driving; Award; Biological Markers; Boston; Brain; Brain imaging; Catchment Area; Cerebrospinal Fluid; Clinic; Clinical; Clinical Investigator; Clinical Research; Cognition; Cognitive; Collaborations; Collection; Consensus; Consent; Cross-Sectional Studies; Data; Dementia; Diagnosis; Diagnostic; Electroencephalography; Ensure; Evaluation; Exposure to; Framingham Heart Study; Funding; Genetic; Genomics; Goals; Knowledge; Late Effects; Life; Manufactured football; Medical center; Memory; Memory Disorders; Methods; Molecular Profiling; Neighborhoods; Neurologic; Neuropsychology; Participant; Pathogenesis; Pathologic; Phenotype; Play; Population Study; Positron-Emission Tomography; Race; Recommendation; Reporting; Research; Research Personnel; Risk Factors; Role; Sampling; Source; Sports; Structure; Target Populations; Translational Research; Universities; Violence; Woman; Work; blood product; chronic traumatic encephalopathy; clinical center; clinical phenotype; cohort; contact sports; data management; data sharing; digital; education research; head impact; health disparity; informant; insight; male; men; mild cognitive impairment; military service; neuropathology; neuropsychiatry; next generation; novel; novel marker; outreach; precision medicine; recruit; research study; statistics; student training; tau Proteins; transmission process

The Boston University Alzheimer’s Disease Research Center Clinical Core (BU ADRC CC) facilitates and conducts cutting-edge research on AD and AD related dementias (ADRDs), including chronic traumatic encephalopathy (CTE). CC participants, and biospecimens and data generated from their participation, support local efforts, cross-ADRC collaborations and national research initiatives. CC investigators are engaged in AD/ADRD research towards several National Alzheimer’s Project Act (NAPA) goals, including population studies, precision medicine, health disparities, biomarkers, diagnosis, mechanisms, and translational and clinical research. The Center is closely integrated and synergistic with the Framingham Heart Study at BU. Research by CC investigators has led to fundamental insights into the role of repetitive head impacts (RHI) from contact sport participation, military service and physical violence in the pathogenesis of AD/ADRD, including CTE. However, CTE cannot be diagnosed during life due to an ill-defined clinical presentation and lack of validated biomarkers. Research has been limited by cross-sectional studies of small samples of male former elite American football players and reliance on retrospective informant reports. To address these knowledge gaps, we expanded our CC in 2018 to integrate participants with exposure to RHI (men and women, across different types of sports and levels of play). This integration is highly aligned with the Center-wide theme to study the late effects of RHI and compare AD, CTE and other ADRDs, vis-à-vis clinical presentation, biomarker profile, genetic and other risks factors, and clinical-pathological correlations. In Aim 1, we will sustain, augment, and characterize the clinical phenotypes and trajectories of an established CC Cohort (CCC). The CCC is comprised of 400 participants, that are >50 years, demographically diverse, representative of Greater Boston and that span the cognitive spectrum. We will collaborate with the Outreach, Recruitment and Engagement Core to continue recruitment of traditional CC participants and expand the number with RHI exposure. We will characterize the neurological, neuropsychological, neuropsychiatric and diagnostic profiles using traditional and novel phenotyping approaches, including digital phenotyping. We will obtain brain donation consent of CC participants and work with the Neuropathology Core to facilitate brain donation. In Aim 2, we will obtain brain imaging, biospecimens and novel biomarkers from the CCC and work with the Data Management & Statistics, Biomarker, and Genomics and Molecular Profiling Cores to integrate biomarker collection, analysis, banking, and distribution. In Aim 3, we will share data and provide a source of well-characterized participants for local and national research studies on AD and ADRD, including CTE. In Aim 4, we will educate trainees to develop the next generation of AD/ADRD clinical investigators. In conclusion, the CC plays a central role in the BU ADRC by engaging research participants and driving activities that reflect the Center’s overall themes, as well as advancing the priorities identified in NAPA recommendations.

波士顿大学阿尔茨海默病研究中心临床核心 (BU ADRC CC) 促进和 对 AD 和 AD 相关痴呆症 (ADRD) 进行前沿研究，包括慢性创伤性痴呆 脑病（CTE）。 CC 参与者，以及他们的参与、支持产生的生物样本和数据 地方努力、跨 ADRC 合作和国家研究计划。 CC调查员正在从事 AD/ADRD 研究旨在实现国家阿尔茨海默病项目法案 (NAPA) 的多项目标，包括人口研究、 精准医学、健康差异、生物标志物、诊断、机制以及转化和临床 研究。该中心与波士顿大学的弗雷明汉心脏研究紧密结合并协同作用。研究 CC 研究人员对接触造成的重复性头部撞击 (RHI) 的作用有了基本的了解 AD/ADRD（包括 CTE）发病机制中参与体育运动、服兵役和身体暴力。 然而，由于临床表现不明确且缺乏经过验证的证据，CTE 无法在一生中进行诊断。 生物标志物。研究受到对美国前男性精英小样本的横断面研究的限制 足球运动员和对回顾性线人报告的依赖。为了解决这些知识差距，我们扩展了 我们的 CC 在 2018 年将接触 RHI 的参与者（男性和女性，不同类型的运动）整合在一起 和游戏级别）。这种整合与研究 RHI 后期影响的中心主题高度一致 并比较 AD、CTE 和其他 ADRD、临床表现、生物标志物概况、遗传和其他 风险因素和临床病理相关性。在目标 1 中，我们将维持、增强和表征 已建立的 CC 队列 (CCC) 的临床表型和轨迹。 CCC 由 400 参与者年龄超过 50 岁，人口结构多样化，代表大波士顿地区，跨越 认知谱。我们将与外展、招聘和参与核心合作，继续 招募传统 CC 参与者并通过 RHI 曝光扩大数量。我们将表征 使用传统和新颖的神经学、神经心理学、神经精神病学和诊断概况 表型分析方法，包括数字表型分析。我们将征得CC参与者的脑部捐赠同意 并与神经病理学核心合作促进大脑捐赠。在目标 2 中，我们将获得大脑成像， 来自 CCC 的生物样本和新型生物标志物，并与数据管理和统计、生物标志物、 基因组学和分子分析核心集成生物标志物收集、分析、银行和 分配。在目标 3 中，我们将共享数据并为本地和本地用户提供具有良好特征的参与者来源。 关于 AD 和 ADRD（包括 CTE）的国家研究。在目标 4 中，我们将教育学员发展 下一代 AD/ADRD 临床研究人员。总之，CC 在 BU ADRC 中发挥着核心作用： 吸引研究参与者并推动反映中心总体主题的活动，以及 推进国家适应行动方案建议中确定的优先事项。